title: Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.
authors: Pellegrino
authors: P
authors: Musto
authors: Angelo Michele
authors: AM
authors: Carella
authors: Michele Mario
authors: MM
authors: Greco
authors: Antonietta
authors: A
authors: Falcone
authors: Grazia
authors: G
authors: Sanpaolo
authors: Carlo
authors: C
authors: Bodenizza
authors: Nicola
authors: N
authors: Cascavilla
authors: Lorella
authors: L
authors: Melillo
authors: Angelo Michele
authors: AM
authors: Carella
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D000069283:Rituximab; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab